Pakistan vs Palestine, State of: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Pakistan
87.0%
in 2024
Palestine, State of
87.0%
in 2024
Pakistan rank
78th
Palestine, State of rank
78th
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Pakistan
- Palestine, State of
How they compare
Pakistan currently reports 87.0% against 87.0% in Palestine, State of, a difference of 0.0%.
Across all 12 years both countries report, Palestine, State of has been ahead every year.
Pakistan ranks 78th and Palestine, State of ranks 78th of 146 countries.
Palestine, State of has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Pakistan | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 76.9% | 98.3% | 21.4% | Palestine, State of |
| 2020s | 84.6% | 93.2% | 8.6% | Palestine, State of |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Pakistan or Palestine, State of?
- Pakistan, at 87.0% against 87.0% in Palestine, State of as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Pakistan and Palestine, State of?
- 0.0%, with Pakistan ahead.
- How many years of comparable data are there for Pakistan and Palestine, State of?
- 12 years are reported by both, from 2013 to 2024.
- How do Pakistan and Palestine, State of rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Pakistan ranks 78th and Palestine, State of ranks 78th of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.